We provide patients with:

- the latest minimally invasive, image-guided techniques for the diagnosis and treatment of lung cancer, esophageal cancer, mesothelioma, thymoma, and cancer that has spread to the lungs.
- the benefit of seeing multiple specialists on one day, in one location
- an individualized treatment and recovery plan
- a comprehensive risk assessment and long-term surveillance program
- access to innovative clinical trials of chemotherapies, surgical techniques, and advanced technologies that are not available at other hospitals
- genomic sequencing

THORACIC CANCER PROGRAM OVERVIEW

MSK’s thoracic cancer program is recognized as one of the world’s finest, ranked fifth out of 51 top-scoring hospitals for urology in U.S. News & World Report.

We provide patients with:

- the latest minimally invasive, image-guided techniques for the diagnosis and treatment of lung cancer, esophageal cancer, mesothelioma, thymoma, and cancer that has spread to the lungs.
- the benefit of seeing multiple specialists on one day, in one location
- an individualized treatment and recovery plan
- a comprehensive risk assessment and long-term surveillance program
- access to innovative clinical trials of chemotherapies, surgical techniques, and advanced technologies that are not available at other hospitals
- genomic sequencing

LOCATIONS

Many of our specialists are centrally located at our Manhattan location. We also have regional outpatient locations at:

- MSK Basking Ridge, New Jersey
- MSK Bergen, New Jersey
- MSK Monmouth, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York
- MSK Westchester, West Harrison, New York

Our Team Leaders

Charles Rudin, MD, PhD
Co-Director, Druckenmiller Center for Lung Cancer Research; Sylvia Hassenfeld Chair in Lung Cancer Research

David Jones, MD
Co-Director, Druckenmiller Center for Lung Cancer Research; Fiona and Stanley Druckenmiller Chair in Lung Cancer

Stephen Solomon, MD
Chief, Interventional Radiology Service

Marc Ladanyi, MD
William J. Ruane Chair in Molecular Oncology

Daniela Molena, MD
Director, Esophageal Surgery Program

William Travis, MD
Director, Thoracic Pathology

REFER A PATIENT

Contact our Physician Access Service directly at

800-525-2225

MSK has insurance contracts with most major health plans in the New York tristate area.

Sign up for OncoNotes, MSK’s clinical updates newsletter.

Go to MSKCC.org, click on the For Health Professionals section, and choose “Sign up for Our E-newsletter.”
WHY CHOOSE MSK FOR THORACIC CANCER CARE?

Leadership

- Our specialists have expertise in specific types of cancer, including KRAS and BRAF mutations, squamous cell lung cancer, and mesothelioma.
- We have some of the world’s most extensive experience with radiation therapy before and after esophageal cancer surgery.
- We have more than 60 thoracic clinical trials underway for a broad range of targeted therapies and immunotherapy agents, and a phase I chimeric antigen receptor T cell therapy trial for mesothelioma and malignant pleural disease.

Expertise

- We are the first hospital in the United States to create a dedicated advanced thoracic cancer team. Our morbidity and mortality rates are among the lowest in the country.
- Our surgical expertise and high volumes allow us to perform thoracic and esophageal surgeries on people who are not surgical candidates elsewhere.
- Our lung-sparing surgical program for thoracic cancer is globally recognized.

By the Numbers

- 1,500+ lung cancer operations per year
- 100+ esophagectomy operations per year
- 12 thoracic surgeons
- 31 thoracic cancer specialists
- 2,000+ procedures per year
- 19 thoracic medical oncologists
- 7 locations

Advanced Technologies

- We perform a large volume of minimally invasive procedures using video-assisted or robotic surgical techniques, resulting in greater precision, fewer complications, and decreased postoperative pain compared with open surgery.
- Our enhanced recovery program results in shorter hospital stays and faster recovery times.
- We routinely utilize MSK-IMPACT™ to test for more than 400 mutations in both rare and common cancers and match tumors with targeted therapies.
- Our 24/7 pathology lab processes digitized images of tissue samples very quickly, including during surgery, to help patients avoid unnecessary procedures.